Angioscopic evaluation of site-specific administration of ReoPro

Steven R. Bailey, Edward Lewis O'Leary, Robert Chilton

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Systemic administration of newer antiplatelet agents such as the GP IIb/IIIa agent ReoPro (Centocor BV Leiden, The Netherlands) has been shown to decrease the early incidence of recurrent ischemia and recurrent myocardial infarction. The currently approved protocol for administration of ReoPro involves an initial weight adjusted bolas followed by a systemic infusion over the next 12 hr. The systemic administration is proposed as the only route of administration because it is stated that the drug must be exposed to circulating platelets. An alternative approach would be to deliver ReoPro locally and allow the platelets to disaggregate only when in contact with the local arterial wall. The optimal method of monitoring the efficacy of such a strategy is to visually assess the presence of platelet rich or red blood cell rich thrombus using angioscopy. We report our initial experience in 12 patients who received local administration of ReoPro using currently approved catheters for local administration of agents into coronary arteries who were evaluated before and after intervention using intracoronary angioscopy. None of the patients received a subsequent 12-hr infusion. There was successful resolution of thrombus in 11 of 12 patients. Recurrent ischemia occurred in one patient without myocardial infarction.

Original languageEnglish (US)
Pages (from-to)181-186
Number of pages6
JournalCatheterization and Cardiovascular Diagnosis
Volume42
Issue number2
DOIs
StatePublished - Oct 1 1997

Fingerprint

Angioscopy
Blood Platelets
Thrombosis
Ischemia
Myocardial Infarction
Platelet Membrane Glycoprotein IIb
Platelet Aggregation Inhibitors
Netherlands
Coronary Vessels
Catheters
Erythrocytes
Weights and Measures
abciximab
Incidence
Pharmaceutical Preparations

Keywords

  • Angioscope
  • Local delivery
  • Thrombus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Angioscopic evaluation of site-specific administration of ReoPro. / Bailey, Steven R.; O'Leary, Edward Lewis; Chilton, Robert.

In: Catheterization and Cardiovascular Diagnosis, Vol. 42, No. 2, 01.10.1997, p. 181-186.

Research output: Contribution to journalReview article

@article{594c0832e58549b18588a87765594208,
title = "Angioscopic evaluation of site-specific administration of ReoPro",
abstract = "Systemic administration of newer antiplatelet agents such as the GP IIb/IIIa agent ReoPro (Centocor BV Leiden, The Netherlands) has been shown to decrease the early incidence of recurrent ischemia and recurrent myocardial infarction. The currently approved protocol for administration of ReoPro involves an initial weight adjusted bolas followed by a systemic infusion over the next 12 hr. The systemic administration is proposed as the only route of administration because it is stated that the drug must be exposed to circulating platelets. An alternative approach would be to deliver ReoPro locally and allow the platelets to disaggregate only when in contact with the local arterial wall. The optimal method of monitoring the efficacy of such a strategy is to visually assess the presence of platelet rich or red blood cell rich thrombus using angioscopy. We report our initial experience in 12 patients who received local administration of ReoPro using currently approved catheters for local administration of agents into coronary arteries who were evaluated before and after intervention using intracoronary angioscopy. None of the patients received a subsequent 12-hr infusion. There was successful resolution of thrombus in 11 of 12 patients. Recurrent ischemia occurred in one patient without myocardial infarction.",
keywords = "Angioscope, Local delivery, Thrombus",
author = "Bailey, {Steven R.} and O'Leary, {Edward Lewis} and Robert Chilton",
year = "1997",
month = "10",
day = "1",
doi = "10.1002/(SICI)1097-0304(199710)42:2<181::AID-CCD18>3.0.CO;2-R",
language = "English (US)",
volume = "42",
pages = "181--186",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Angioscopic evaluation of site-specific administration of ReoPro

AU - Bailey, Steven R.

AU - O'Leary, Edward Lewis

AU - Chilton, Robert

PY - 1997/10/1

Y1 - 1997/10/1

N2 - Systemic administration of newer antiplatelet agents such as the GP IIb/IIIa agent ReoPro (Centocor BV Leiden, The Netherlands) has been shown to decrease the early incidence of recurrent ischemia and recurrent myocardial infarction. The currently approved protocol for administration of ReoPro involves an initial weight adjusted bolas followed by a systemic infusion over the next 12 hr. The systemic administration is proposed as the only route of administration because it is stated that the drug must be exposed to circulating platelets. An alternative approach would be to deliver ReoPro locally and allow the platelets to disaggregate only when in contact with the local arterial wall. The optimal method of monitoring the efficacy of such a strategy is to visually assess the presence of platelet rich or red blood cell rich thrombus using angioscopy. We report our initial experience in 12 patients who received local administration of ReoPro using currently approved catheters for local administration of agents into coronary arteries who were evaluated before and after intervention using intracoronary angioscopy. None of the patients received a subsequent 12-hr infusion. There was successful resolution of thrombus in 11 of 12 patients. Recurrent ischemia occurred in one patient without myocardial infarction.

AB - Systemic administration of newer antiplatelet agents such as the GP IIb/IIIa agent ReoPro (Centocor BV Leiden, The Netherlands) has been shown to decrease the early incidence of recurrent ischemia and recurrent myocardial infarction. The currently approved protocol for administration of ReoPro involves an initial weight adjusted bolas followed by a systemic infusion over the next 12 hr. The systemic administration is proposed as the only route of administration because it is stated that the drug must be exposed to circulating platelets. An alternative approach would be to deliver ReoPro locally and allow the platelets to disaggregate only when in contact with the local arterial wall. The optimal method of monitoring the efficacy of such a strategy is to visually assess the presence of platelet rich or red blood cell rich thrombus using angioscopy. We report our initial experience in 12 patients who received local administration of ReoPro using currently approved catheters for local administration of agents into coronary arteries who were evaluated before and after intervention using intracoronary angioscopy. None of the patients received a subsequent 12-hr infusion. There was successful resolution of thrombus in 11 of 12 patients. Recurrent ischemia occurred in one patient without myocardial infarction.

KW - Angioscope

KW - Local delivery

KW - Thrombus

UR - http://www.scopus.com/inward/record.url?scp=0030830096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030830096&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0304(199710)42:2<181::AID-CCD18>3.0.CO;2-R

DO - 10.1002/(SICI)1097-0304(199710)42:2<181::AID-CCD18>3.0.CO;2-R

M3 - Review article

VL - 42

SP - 181

EP - 186

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 2

ER -